-

Bruker Introduces Routine Gradient Spectroscopy and Robust, Industry-Standard PAL® Automation on High-Performance Fourier™ 80 Benchtop FT-NMR System

ZUERICH--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announces the European launch of the high-performance Fourier™ 80 system, a next-generation, 80 MHz Fourier Transform Nuclear Magnetic Resonance (FT-NMR) benchtop spectrometer, now with major new capabilities.

The Fourier 80 now is routinely equipped for gradient spectroscopy and offers the option of an industry-standard CTC PAL® sample changer. The Fourier 80 is suitable for organic or medicinal chemistry analysis, NMR teaching, synthesis verification or routine analysis in any chemistry laboratory. Equipped with a novel, ultra-stable 80 MHz permanent magnet, it requires no cryogens, water cooling, or special lab infrastructure.

The Fourier 80 has been designed for highest data quality and stability at 80 MHz, with excellent line-shape, resolution and sensitivity in 80 MHz homonuclear 1H or heteronuclear 1H/13C FT-NMR experiments. The latest version now offers even greater sensitivity and 20% improved resolution performance. It can be operated by the easy-to-use GoScan™ software for NMR beginners, or by Bruker's TopSpin™ NMR software with the extensive TopSpin library of 1D and 2D homonuclear and proton-carbon heteronuclear experiments and pulse programs.

The latest version of the Fourier 80 now includes a pulsed field gradient which has been used in high-field NMR spectroscopy for decades to quickly and conveniently obtain essentially artifact-free spectra. Gradients allow users to enhance solvent or water suppression, perform DOSY experiments, and acquire two-dimensional NMR spectra within minimal experiment time.

Another new feature is the option of an industry-standard, robust and high-throughput PAL sample changer. Fourier 80 users with the PAL sample changer can run up to 132 samples, including 12 reference samples, thereby dramatically increasing throughput and efficiency. GoScan now also operates the sample changer to run samples overnight or over a weekend.

The Fourier 80 offers workflows and protocols for academic, pharma and industrial chemistry research, as well as for forensics and organic synthesis control. It can be incorporated into science education to introduce students to the power of FT-NMR. An optional teaching package with recommended experiments and spectra interpretation guide is also available.

Dr. Falko Busse, President of the Bruker BioSpin Group, commented: "Bruker is proud to offer the Fourier 80 with new, industry-leading capabilities like routine gradient spectroscopy, and a robust, well-accepted PAL sample changer. High-performance 80 MHz FT-NMR can now be used efficiently in any chemistry lab, just like benchtop mass spectrometers or FT-IR systems which have proliferated in chemistry labs for decades. The Fourier 80 is providing education packages to give instructors tools to introduce young scientists to the power of FT-NMR. With the Fourier 80, we further 'democratize' the many applications of NMR."

Join the launch of the Fourier 80 starting on October 19th at www.bruker.com/Fourier80. Watch exclusive content describing the new capabilities and hear from experts. Visitors will be able to ask questions and interact with members of the Bruker NMR team.

® PAL is a registered trademark of CTC Analytics AG

About Bruker Corporation (Nasdaq: BRKR)

Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy and nanoanalysis, and in industrial applications, as well as in cell biology, preclinical imaging, clinical phenomics and proteomics research and clinical microbiology. For more information, please visit: www.bruker.com.

Contacts

Investor Contact:
Miroslava Minkova
Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com

Bruker Corporation

NASDAQ:BRKR

Release Summary
Bruker Introduces Routine Gradient Spectroscopy and Industry-Standard PAL® Automation on High-Performance Fourier™ 80 Benchtop FT-NMR System
Release Versions

Contacts

Investor Contact:
Miroslava Minkova
Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: Investor.Relations@bruker.com

Media Contact:
Thorsten Thiel, Ph.D.
VP of Group Marketing
Bruker BioSpin
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com

More News From Bruker Corporation

Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

THUN, Switzerland--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) today announced the acquisition of an additional 60% ownership stake in TOFWERK AG, a Switzerland-based innovator in ultra-fast time-of-flight (TOF) mass spectrometry technology for small molecule applied markets, consolidating Bruker’s ownership to 100%. The transaction adds ultra-fast TOF-MS technology for small-molecule markets, including atmospheric chemistry research, air quality monitoring, exposomics, foods, flavors &a...

Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the “Events...

RI Research Instruments Announces Major Orders for Enabling Technology for the Gamma-Ray Source of the Extreme Light Infrastructure (ELI)

BERGISCH GLADBACH, Germany--(BUSINESS WIRE)--RI Research Instruments, a company that is majority-owned by Bruker Corporation (Nasdaq: BRKR), today announced orders for key components and enabling subsystems for the research gamma ray source of the Extreme Light Infrastructure – Nuclear Physics (ELI-NP) at the Horia Hulubei National Institute of Physics and Nuclear Engineering (IFIN-HH) in Romania. The total value of these ELI contracts is approximately €35 million (more than USD $40 million), w...
Back to Newsroom